{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"SBT6050 plus trastuzumab deruxtecan\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntrastuzumab deruxtecan: 6.4 mg/kg by IV infusion in 21-day cycles","id":"EG000","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"SBT6050 + T-DXd (6.4 mg/kg)"},{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"SBT6050 plus tucatinib and trastuzumab\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntucatinib: 300 mg by mouth (PO) twice daily (BID)\n\ntrastuzumab: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles","id":"EG001","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"SBT6050 + Tucatinib + Trastuzumab"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Cytokine release syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Injection site reaction"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Decreased appetite"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Palmar-plantar erythrodysesthesia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1},{"groupId":"EG001","numAffected":0,"numAtRisk":1}],"term":"Bloating"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Constipation"}],"timeFrame":"18 weeks"}